Fetuin-B (FETUB): a Plasma Biomarker Candidate Related to the Severity of Lung Function in COPD.
Fetuin-B (FETUB): a Plasma Biomarker Candidate Related to the Severity of Lung Function in COPD.
复制标题
胎球蛋白-B (FETUB)：与 COPD 肺功能严重程度相关的血浆候选生物标志物
DOI：
10.1038/srep30045
复制
发表时间：
2016-07-22
影响因子：
4.6
通讯作者：
He B
中科院分区：
文献类型：
--
作者：
Diao WQ;Shen N;Du YP;Liu BB;Sun XY;Xu M;He B
COPD患者肺功能进展的生物标志物目前还很缺乏。通过基于iTRAQ的蛋白质组学鉴定血浆胎球蛋白B（FETUB），并在另一组中通过ELISA进行验证。在一年随访计划中收集了关于急性加重（AE）的信息。COPD患者中的FETUB浓度（1652 ± 427 ng/ml）高于对照组（1237 ± 77 ng/ml）。GOLD II组（1762 ± 427 ng/ml）、III组（1650 ± 375 ng/ml）和IV组（1800 ± 451 ng/ml）中的FETUB浓度高于对照组（1257 ± 414 ng/ml）和GOLD I组（1345 ± 391 ng/ml）。ROC表明，FETUB可区分COPD患者与对照组（AUC 0.747，95% CI：0.642-0.834），也可区分GOLD II、III和IV与GOLD I COPD患者（AUC：0.770，95% CI：0.634-0.874）。FETUB和纤维蛋白原联合治疗的效果更好（AUC：0.804，95% CI：0.705-0.881）。FETUB还可预测AE（AUC：0.707，95% CI：0.566-0.824）或频繁AE（AUC：0.727，95% CI：0.587-0.840）的发生。FETUB浓度与FEV1%pred呈负相关（r=-0.446，p = 0.000），与RV%pred（r= 0.317，p = 0.004）、RV/TLC%（r= 0.360，p = 0.004）、CT肺气肿%（r= 0.322，p = 0.008）和肺功能分级（r= 0.437，p = 0.000）呈正相关。总之，FETUB可能有助于COPD的诊断和管理，作为其他标志物的补充。
Biomarkers for the progression of lung function in COPD are currently scarce. Plasma fetuin-B (FETUB) was identified by iTRAQ-based proteomics and was verified by ELISA in another group. Information regarding acute exacerbation (AE) was collected in a one-year follow-up programme. FETUB concentrations (1652 ± 427 ng/ml) were greater in COPD patients than in controls (1237 ± 77 ng/ml). The concentrations of FETUB in GOLD II (1762 ± 427 ng/ml), III (1650 ± 375 ng/ml) and IV (1800 ± 451 ng/ml) groups were greater than those in the controls (1257 ± 414 ng/ml) and the GOLD I (1345 ± 391 ng/ml) group. ROCs indicated that FETUB distinguished COPD patients from controls (AUC 0.747, 95% CI: 0.642–0.834) and also GOLD II, III and IV from GOLD I COPD patients (AUC: 0.770, 95% CI: 0.634–0.874). The combination of FETUB and fibrinogen performed better (AUC: 0.804, 95% CI: 0.705–0.881). FETUB also predicted the occurrence of AE (AUC: 0.707, 95% CI: 0.566–0.824) or frequent AE (AUC: 0.727, 95% CI: 0.587–0.840). FETUB concentrations were negatively correlated with FEV1%pred (r= −0.446,p= 0.000) and positively correlated with RV%pred (r= 0.317,p= 0.004), RV/TLC% (r= 0.360,p= 0.004), CT emphysema% (r= 0.322,p= 0.008) and grades of lung function (r= 0.437,p= 0.000). In conclusion, FETUB is likely to assist the diagnosis and management of COPD as a complement for other markers.